The World Health Organization (WHO) is a specialized agency of the United Nations created in 1948 with the primary responsibility for international health matters and public health. The WHO Regional Office for Europe is one of six regional offices throughout the world, each with its own programme geared to the particular health conditions of the countries it serves.

Member States

Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
Macedonia
Montenegro
Netherlands
Norway
Poland
Portugal
Republic of Moldova
Romania
Russian Federation
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
The former Yugoslav Republic of Macedonia
Turkey
Turkmenistan
Monaco
United Kingdom
Uzbekistan

World Health Organization
Regional Office for Europe
Scherfigsvej 8, DK-2100 Copenhagen Ø, Denmark
Tel.: +45 39 17 17 17. Fac.: +45 39 17 18 18. E-mail: postmaster@euro.who.int
Web site: www.euro.who.int
10th meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)

Copenhagen, Denmark

29-30 September 2009
Abstract

The European Technical Advisory Group of Experts on Immunization (ETAGE) met on 29–30 September 2009 to review and discuss immunization activities and developments in the WHO European Region and provide advice to the WHO Regional Office on appropriate activities.

Following the advice of the 9th ETAGE meeting, a full day was spent on discussing surveillance for vaccine preventable diseases. EU Member States are currently required to report surveillance data to both WHO and to ECDC. Establishment of a multiagency working group to rationalize and harmonize reporting requirements was urged.

Faced with a large potential funding gap for 2010–2011, WHO was advised to establish a meeting with funding partners and potential partners as soon as possible, to extend collaborative activities with partner agencies and immunization initiatives, and continue to outsource activities to WHO collaborating centres and other technical institutions where possible.

Keywords

VACCINES
IMMUNIZATION PROGRAMS
MEASLES - PREVENTION AND CONTROL
RUBELLA - PREVENTION AND CONTROL
EPIDEMIOLOGIC SURVEILLANCE
FINANCING, HEALTH
STRATEGIC PLANNING.
GUIDELINES
EUROPE

Address requests about publications of the WHO Regional Office for Europe to:
Publications
WHO Regional Office for Europe
Scherfigsvej 8
DK-2100 Copenhagen Ø, Denmark

Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office web site (http://www.euro.who.int/pubrequest).

© World Health Organization 2010

All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The views expressed by authors, editors, or expert groups do not necessarily represent the decisions or the stated policy of the World Health Organization.
### Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviations</td>
<td>iv</td>
</tr>
<tr>
<td>Executive summary</td>
<td>v</td>
</tr>
<tr>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>Opening Statements</td>
<td>1</td>
</tr>
<tr>
<td>Report: Progress made since the last ETAGE meeting</td>
<td>2</td>
</tr>
<tr>
<td>Technical Session 1: Surveillance of vaccine-preventable diseases in the Region: experiences and challenges from Member States, ECDC and WHO Regional Office for Europe</td>
<td>2</td>
</tr>
<tr>
<td>Technical Session 2: Roles and status of advisory groups at global, regional, and national levels (SAGE, ETAGE and NITAG)</td>
<td>4</td>
</tr>
<tr>
<td>Technical Session 3: Vaccine for pandemic (H1N1) 2009 influenza</td>
<td>5</td>
</tr>
<tr>
<td>Technical Session 4: TDI Strategic Plan</td>
<td>6</td>
</tr>
<tr>
<td>Technical session 5: Status of 2010 goal for measles and rubella elimination goal</td>
<td>7</td>
</tr>
<tr>
<td>Recommendations</td>
<td>7</td>
</tr>
<tr>
<td>Annex 1. Programme</td>
<td>10</td>
</tr>
<tr>
<td>Annex 2. Participants</td>
<td>12</td>
</tr>
</tbody>
</table>
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDC</td>
<td>United States Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>ECDC</td>
<td>European Centre for Disease Control and Prevention</td>
</tr>
<tr>
<td>EIW</td>
<td>European Immunization Week</td>
</tr>
<tr>
<td>ETAGE</td>
<td>European Technical Advisory Group of Experts on Immunization</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>EUVAC.NET</td>
<td>European Surveillance Community Network for Vaccine Preventable Diseases</td>
</tr>
<tr>
<td>GAVI</td>
<td>Global Alliance for Vaccines and Immunization</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>human immunodeficiency virus/acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>JRF</td>
<td>WHO/UNICEF Joint Reporting Form</td>
</tr>
<tr>
<td>NITAG</td>
<td>National Immunization Technical Advisory Group</td>
</tr>
<tr>
<td>SAGE</td>
<td>Strategic Advisory Group of Experts on Immunization</td>
</tr>
<tr>
<td>SAM</td>
<td>Surveillance, Monitoring and Evaluation Team</td>
</tr>
<tr>
<td>SIVAC</td>
<td>Supporting National Independent Immunization and Vaccine Advisory Committees initiative</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TDI</td>
<td>Targeted Diseases and Immunization Team</td>
</tr>
<tr>
<td>TESSy</td>
<td>The European Surveillance System</td>
</tr>
<tr>
<td>UNICEF</td>
<td>United Nations Children’s Fund</td>
</tr>
<tr>
<td>VPD</td>
<td>Vaccine-preventable diseases</td>
</tr>
<tr>
<td>WER</td>
<td>Weekly Epidemiological Record</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
Executive summary

The European Technical Advisory Group of Experts on Immunization (ETAGE) held its tenth meeting on 29–30 September 2009 in the WHO Regional Office for Europe, Copenhagen, Denmark. Members of National Immunization Technical Advisory Groups (NITAGs) from nine countries and the chairperson of SAGE participated in the meeting. Main topics for discussion included the status and nature of reporting systems for surveillance of vaccine preventable diseases in the Region, most recent recommendations from the SAGE, availability and recommendations for use of vaccine against pandemic H1N1 2009 influenza, status of the TDI Strategic Plan 2010–2015, and likelihood of achieving the 2010 measles elimination regional target.

Based on a recommendation from the 9th ETAGE meeting a full day session on vaccine preventable diseases surveillance, including representatives from WHO, ECDC, CDC and selected Member States, was held. This session focussed on the types and sources of surveillance information and on efforts to improve both the quality and timeliness reported by Member States. It also addressed the issue of additional burdens placed on EU Member States in meeting the reporting requirements of both WHO and ECDC. A panel discussion revealed that the data needs of WHO and ECDC are not identical and the surveillance and reporting systems established by WHO and ECDC are not duplicative. Although there are overlaps, these are systems performing different but complementary functions. As such, ETAGE recommended a joint working group be established to develop common sets of reporting variables and a common data reporting platform that will meet the information needs of both WHO and ECDC.

During this session ETAGE also heard that for the 2010–2011 funding biennium the Regional Office faces a funding gap for immunization-related activities of approximately 40% of the proposed working budget. In the current global economic environment attracting funding to fill this gap is expected to be difficult. Failure to secure sufficient funding will result in reduced levels of staffing, reduction in the scope of activities, and place severe restrictions on the capacity of WHO to outsource planned activities. ETAGE recommended a partner meeting for mobilization of resources for immunization and VPD surveillance in the European Region be held as soon as possible.

WHO has been supporting the establishment of NITAGs in Member States. These national expert committees meet to provide advice on existing immunization policies and on the introduction of new policies and strategies. A recent survey has shown that 34 of the 53 Regional Member States, have standing NITAGs, and an additional 7 have groups that convene on an ad hoc basis in response to special circumstances. WHO is working with Member States and with SIVAC to strengthen existing NITAGs and support those countries without Advisory Groups to establish them.

Within the WHO European Region, 48 of 53 Member States have now confirmed cases of pandemic (H1N1) 2009 influenza infection, with over 56 000 laboratory-confirmed cases and 176 deaths in laboratory-confirmed cases. Experience gained in Australia, South Africa and countries of South America over the past southern hemisphere influenza season provides some indication of what to expect from pandemic influenza in Europe over the winter season. ETAGE endorsed the SAGE recommendations that immunization against pandemic H1N1 2009 influenza should not alter existing plans for immunization of target groups with vaccine against seasonal influenza, or delay or adjust routine immunization schedules for other antigens. ETAGE
also urged Member States to follow the SAGE recommendations on prioritization of groups for receipt of pandemic (H1N1) 2009 influenza vaccine.

A draft of the TDI Strategic Plan 2010–2014 has been prepared; this draft will be completed as soon as possible and forwarded to the ETAGE and key partners for review and comment. It is intended that the plan will be completed, including comments and amendments received, during a planned retreat in December 2009, and submitted for clearance and publishing by the Regional Office.

There has been a steady decline in the Regional incidence of measles cases over the past decade, but the level remains at approximately 1 per 100 thousand population. Vaccine coverage in most Member States is now high, but the number of countries with coverage less than 95% of target has recently increased, and several now need to conduct supplementary immunization activities to combat low coverage, particularly in subnational areas and higher risk populations. The Regional Office has evaluated immunization services in the Region and considers that the 2010 measles elimination goal is unlikely to be achieved in at least 10 Member States. WHO is working with these countries to address immunity gaps and pockets of low coverage, improve overall measles vaccine coverage, strengthen surveillance, and develop systems for the verification and validation of coverage and surveillance data.
Introduction

The European Technical Advisory Group of Experts on Immunization (ETAGE) meets twice a year to review the progress of the Targeted Diseases and Immunization (TDI) and Surveillance, Monitoring and Evaluation (SAM) Teams, formerly the Vaccine Preventable Diseases Programme (VPD), towards the European Regional disease prevention goals. The 10th meeting of the ETAGE was held at the WHO Regional Office for Europe, Copenhagen, on 29 and 30 September 2008.

Professor Pierre Van Damme chaired the meeting and Dr Ray Sanders was rapporteur. Dr David Mercer, Unit Head a.i. of the Communicable Diseases Unit, welcomed ETAGE members, representatives of partner agencies and Regional immunization initiatives, representative of selected Member States, and staff from WHO headquarters to the meeting.

The objectives of the meeting were to:

- request guidance from ETAGE towards the regional goals;
- review surveillance systems and reporting mechanisms for vaccine-preventable diseases in the Region;
- provide an update on the progress towards the 2010 measles and rubella elimination goal in the Region;
- review the WHO Regional Office for Europe’s response to availability and deployment of pandemic (H1N1) 2009 influenza vaccines;
- review SAGE recommendations and the role of National Immunization Technical Advisory Groups in implementing SAGE recommendations; and
- provide updates from the Communicable Diseases Unit.

Opening Statements

Dr Mercer welcomed the group and participants on behalf of WHO, and highlighted the important role ETAGE plays in setting the technical direction and priorities for the immunization programme in the WHO European Region. Since the last ETAGE meeting, administrative changes within the Regional Office, in terms of structural reorganization, have continued. Several countries in the European Region have also suffered outbreaks of pandemic (H1N1) 2009 influenza. Responding to these challenges has been taxing on Regional Office staff, and made it difficult for the secretariat to complete all of the tasks set during the last ETAGE meeting.

In addition to its activities in providing advice and technical support to the WHO Communicable Diseases Unit, ETAGE also has an important advocacy role, particularly for achieving the Regional measles and rubella elimination goals. WHO also looks to ETAGE to provide advice on developing a consensus strategy for vaccine preventable diseases surveillance reporting, and particularly for fostering concordance between WHO and ECDC in establishing a common reporting system. In the wake of the global economic downturn, WHO looks to the ETAGE for advice on making best possible use of available resources.
Professor Van Damme reminded the ETAGE of their responsibility to provide independent review and expert technical input to the WHO European Region’s immunization programme, with the objectives of facilitating and accelerating the achievement of the Regional targets. He also reminded participants of the importance of infectious disease surveillance to Member States of the Region.

**Report: Progress made since the last ETAGE meeting**

Responding to the pandemic (H1N1) 2009 influenza outbreaks in several Member States and to the ongoing structural reorganizations within WHO have placed constraints on WHO Regional Office staff in completing tasks set by ETAGE at its last meeting. As a result, activities have necessarily been prioritized. Highest priority activities have been completed, but some remain in progress and others have been postponed. ETAGE recognized the need for prioritization of activities, and approved the order of prioritization.

One of the delayed activities is the revision, publication and distribution of the TDI Strategic Plan 2010–2014. Revision of the plan has now been completed, and ETAGE was requested to review the draft document. When the review process has been completed the final draft will be published and distributed electronically as a working document that can be periodically reviewed and revised as necessary. It is anticipated the document will be finalized and cleared by the end of the calendar year.

The Regional Office is currently exploring the feasibility of developing a web page for posting key recommendations and documents produced by the national advisory committees for immunization. It is expected that the web site will be launched early next year.

Although it is now unlikely that the Region will meet its 2010 goal of measles and rubella elimination, the Regional goal has not yet been changed. Due to the need to focus activities on pandemic influenza vaccines, the proposed measles/rubella meeting with key Member States from western Europe has been postponed to early 2010. The Regional Office continues to monitor Member States reporting measles outbreaks and provides advice on evaluation of susceptible populations. A consultation will be held in January 2010 to establish a Regional Verification Committee for measles and rubella elimination. Updated surveillance guidelines have been published, and the Regional Office is working with Member States on adapting rubella case-based surveillance and establishing sentinel surveillance for congenital rubella syndrome.

**Technical Session 1: Surveillance of vaccine-preventable diseases in the Region: experiences and challenges from Member States, ECDC and WHO Regional Office for Europe**

The WHO/UNICEF Joint Reporting Form (JRF) is used to collect information from Member States on their immunization and surveillance activities on an annual basis. Information reported on the JRF is submitted by the Ministry or Department of Health and constitutes the official data for the country. Many Member States have problems in completing the forms by the submission deadlines, and some cannot complete all of the required data fields, particularly routine vaccine coverage. By the time the Regional data has been collected, cleaned, analysed and published it is
a year old. These data are useful for planning, trend analysis and advocacy, but is not useful for outbreak detection and response.

Annual data on TB and HIV/AIDS infections is collected in collaboration with ECDC, through the TESSy platform maintained by ECDC. Both WHO and ECDC collect monthly data on measles and rubella infections, with some Member States reporting through EUVAC.NET for ECDC. Twelve Member States also provide monthly surveillance data on diphtheria. WHO continues to maintain weekly reporting of AFP and associated enterovirus and environmental sampling systems. There is also ad hoc reporting of sentinel surveillance and supplementary immunization activities.

The main challenge for WHO is to expand the number of diseases reported on a monthly basis but at the same time to improve reporting compliance and the quality. This requires working closely with Member States to improve national data collection and reporting systems.

ECDC collects surveillance data from EU Member States and is committed to strengthening surveillance systems in these countries. ECDC collects surveillance data from nationally nominated “Competent Bodies” that include national institutes, centres of excellence and recognized disease experts. As such, the data collected are not always fully compatible with that collected by WHO from the Health Ministries.

A number of EC-funded disease surveillance networks and initiatives existed in Europe prior to the establishment of ECDC. Of these the European Union Invasive Bacterial Infections Surveillance Network (EU-IBIS) transferred to ECDC in October 2007 and the Diphtheria Surveillance Network (DIPNET) will transfer in January 2010. The Surveillance Community Network for Vaccine-preventable Diseases (EUVAC.NET) is granted until February 2011. A decision will be made on its possible long-term future before this date. EUVAC.NET collects surveillance data on measles and other childhood vaccine-preventable diseases including pertussis, rubella (and congenital rubella syndrome), mumps and varicella. It is intended that a routine monthly reporting system for these diseases will be established.

A panel discussion, chaired by Professor David Salisbury, posed the questions (i) what is the objective or purpose of surveillance, and (ii) what is the timeliness of surveillance in terms of the time taken for information to move from case investigation to highest level reporting?

WHO surveillance functions through national governments and national programmes and has both process indicators and outcome indicators that are evaluated separately. For WHO, the primary objectives of surveillance are to tailor support and assistance that is provided to Member States, and to monitor progress made by Member States, in controlling infectious diseases. The Regional Office also contributes data to global surveillance systems. With regard to timeliness, data collected through the JRF are obviously not timely, in the sense of being immediate, but they provide information for planning and advocacy. Data collected from the monthly and weekly reporting systems, when they are fully operational, are used to provide a rapid response to needs. This is particularly important for diseases covered by the IHR(2005) reporting requirements.

A primary objective of ECDC is to strengthen infectious disease surveillance in Europe. A main focus for ECDC is quality, so that data is comparable and can be analysed and shared. It attempts this through institutionalization of communications between Competent Bodies and harmonization of data and systems. The use of Competent Bodies, which includes National
Infectious Disease institutes, state epidemiologists and local disease experts, greatly extends the influence of ECDC into national surveillance systems. Timeliness of data collection and reporting systems is disease specific. Reporting of influenza data is on a weekly basis, measles and rubella on a monthly basis, and data on other vaccine-preventable diseases is on an annual basis.

The data needs of WHO and ECDC are not identical and the surveillance and reporting systems established by WHO and ECDC are not duplicative, but are systems performing different, complementary functions. As such, it should be possible to develop common sets of reporting variables and a common data reporting platform that will meet the information needs of both WHO and ECDC. This would avoid the current situation where countries are requested to submit two similar, but different data reports to WHO and ECDC.

In several Member States disease surveillance systems remain in a state of transition. Reporting systems that formerly provided data only for planning and trend analysis are being revised to provide information for action. In many western European countries, surveillance systems have been established that are both sensitive and rapidly responsive. These countries provide model systems of effectiveness and efficiency that are still some way from being realized in many other countries. Timeliness and completeness of investigation, and timeliness and quality of reporting remain problems in several Member States. In many countries with health care systems in transition, primary health care doctors and nurses are not aware of the importance of disease surveillance and are not fully responsive to the needs of surveillance systems. More training is required, and greater emphasis should be placed on the importance of surveillance to national disease control programmes. It is also important to recognize that new and novel surveillance activities and protocols are being developed, and investigation of these advances and innovations may be beneficial to Member States struggling to establish more traditional surveillance systems. Information on advances and innovations in surveillance should be provided to Member States by WHO and ECDC through a common, easily accessed information distribution and feedback platform.

The new funding biennium for WHO starts in January 2010, and as in previous biennia, there is a gap between the funds required for planned activities and the funds currently pledged. This biennium, however, the funding gap is larger than usual, being approximately 40% of the proposed working budget. In the current global economic environment attracting funding to fill this gap is expected to be difficult. Failure to secure sufficient funding will result in reduced levels of staffing, reduction in the scope of activities, and place severe restrictions on the capacity of WHO to outsource activities. Currently 64% of funds for the Region are provided by two partners, CDC Atlanta and GAVI, and there is an urgent need to increase the number of Regional partners. Furthermore, 88% of funds received by the Region are strictly linked to specific activities. While these funds are welcomed, strict linking can reduce the capacity of the Regional Office to make best use of available funds for highest priority activities. There is an urgent need for greater proportion of funds received to be for unspecified expenditures.

**Technical Session 2: Roles and status of advisory groups at global, regional, and national levels (SAGE, ETAGE and NITAG)**

SAGE is WHO’s principle advisory group on immunization and vaccine-preventable diseases. The group has 15 members, appointed by the WHO Director General, meets twice a year and
publishes recommendations from meetings in the Weekly Epidemiological Record (WER). SAGE maintains strong links with the Regional advisory groups, providing advice and guidance to these groups and responding to information, queries and requests from them.

WHO has been supporting the establishment of National Immunization Technical Advisory Groups (NITAGs) in Member States. These national expert committees meet to provide advice on existing immunization policies and on the introduction of new policies and strategies. They represent a technical resource to assist national authorities in evidence-based decision-making, empowering governments to accept stewardship of national immunization programmes. They also act to resist pressure from any interest group, including vaccine manufacturers, increase credibility of national programmes, and promote a more comprehensive approach to the health of national populations. In order to strengthen links between ETAGE and NITAGS, WHO invited members of NITAGs from nine countries in the Region to participate in the 10th meeting of the ETAGE.

The Regional Office has recently conducted a survey of the status of NITAGs in Member States. Of the 53 Regional Member States, 34 have standing NITAGs, and an additional 7 have groups that convene on an ad hoc basis in response to special circumstances. Of the 34 standing NITAGs 19 have formally written terms of reference, 27 have members with at least 5 years experience in the 5 basis areas of expertise recommended by WHO, 22 meet on at least an annual basis, and 18 require members to declare any conflict of interests. Regional WHO guidelines on establishing and maintaining NITAGs have been drafted and will be distributed next year. Plans for the development of a Regional web site, for sharing experience of best practices, are also in hand, and WHO is exploring the possibility of establishing supporting networks, through twinning and increased collaboration with partners such as the Supporting National Independent Immunization and Vaccine Advisory Committees initiative (SIVAC).

The SIVAC initiative is supported by Agence de Médecine Préventive and the International Vaccine Institute, and works with GAVI-eligible countries worldwide. The initiative works with eligible Member States to establish a project infrastructure and develop partnerships to ensure coordination with other global and regional efforts for improving evidence-based decision-making in immunization policies and programmes. SIVAC is currently in discussion with the Regional Office regarding inclusion of European Member States in the initiative and is working collaboratively to align and support the TDI Strategic Plan. Plans exist to support development of a NITAG in Romania in 2010, with the possibility of supporting additional countries after 2010. SIVAC also plans to support Kyrgyzstan in strengthening its NITAG to meet international standards, with the possibility of supporting existing NITAGs in other countries after 2010.

Technical Session 3: Vaccine for pandemic (H1N1) 2009 influenza

Within the WHO European Region, 48 of 53 Member States have now confirmed cases of pandemic (H1N1) 2009 influenza infection, with over 56 000 laboratory-confirmed cases and 176 deaths in laboratory-confirmed cases. Experience gained in Australia, South Africa and countries of South America over the past southern hemisphere influenza season provides some indication of what to expect from pandemic influenza in Europe over the winter season. Generally, the southern hemisphere influenza season was dominated by pandemic (H1N1) 2009 influenza virus, with the median age of cases being around 20 years of age, and the median age of laboratory-confirmed case deaths being approximately 40 years of age. The majority of
reported cases presented with uncomplicated influenza-like illness that resolved without antiviral treatment. The case fatality rate (CFR) remained at less than 1% of confirmed cases, with the majority of these having pre-existing underlying medical conditions. Although virus isolates analysed to date show no antigenic diversity from candidate vaccine strains, the genetic and antigenic evolution of this virus remains unpredictable.

In July 2009, the SAGE held an extraordinary meeting in Geneva to discuss issues and make recommendations related to vaccine for the pandemic (H1N1) 2009 influenza. SAGE recommended:

- immunization of health care workers (1–2% of population) be given first priority;
- a stepwise approach is adopted to vaccinate particular groups: based on country epidemiology and objectives:
  - pregnant women (2% of the world population)
  - those aged >6 months with one or more chronic medical conditions
  - healthy young adults >15–49 years;
  - healthy children
  - healthy adults >49–65 years
  - healthy adults >65 years

The WHO Regional Office for Europe has recently conducted a survey to assess the level and status of access of countries to pandemic vaccine and to identify their needs. Technical assistance is being provided to Member States through a series of workshops targeted on improving country-level planning capacity for vaccine management and delivery. Further technical assistance will be provided to Member States in need of operational planning for vaccination. Collaboration with international partners is being conducted through weekly tele- and video-conferences with the European Commission, ECDC, WHO headquarters and other Regional Offices to share information and to discuss strategies. When vaccine becomes available, a close follow up of vaccination response, including vaccine safety, is planned by WHO. Outcome indicators, including disease incidence, hospitalizations and school attendance have been established for monitoring the impact of the vaccination response.

**Technical Session 4: TDI Strategic Plan**

The Targeted Diseases and Immunization (TDI) strategic plan, 2010–2014 provides a framework for Regional planning and activity implementation that is aligned with the WHO mid-term strategic plan and under the strategic direction of the Global Immunization Vision and Strategies (2006–2015). The plan has three strategic areas: immunization strengthening; targeted disease initiatives; and surveillance, laboratories and monitoring. A draft of the plan has been prepared; this draft will be completed as soon as possible and forwarded to the ETAGE and key partners for review and comment. It is intended that the plan will be completed, including comments and amendments received, during a planned retreat in December 2009, and submitted for clearance and publishing by the Regional Office. As the strategic plan is a living document, it will be reviewed bi-annually and updated and revised as needed.
Technical session 5: Status of 2010 goal for measles and rubella elimination goal

There has been a steady decline in the Regional incidence of measles cases over the past decade, but the level remains at approximately 1 per 100 thousand population. Vaccine coverage in most Member States is now high, but the number of countries with coverage less than 95% of target has recently increased, and several now need to conduct supplementary immunization activities to combat low coverage, particularly in subnational areas and higher risk populations.

Suboptimal immunization coverage led to measles outbreaks and resurgence of indigenous measles in several western European countries. Six Member States: Bulgaria, France, Ireland, Germany, Switzerland and the United Kingdom, together representing 25% of the Region’s population, accounted for 91% of total measles cases in 2009 to date. The Regional Office has evaluated immunization services in Member States and considers that the 2010 measles elimination goal is unlikely to be achieved in at least 10 Member States. WHO is working with these countries to address immunity gaps and pockets of low coverage, improve overall measles vaccine coverage, strengthen surveillance, and develop systems for the verification and validation of coverage and surveillance data.

The Regional Office is also developing a strategy and framework for documenting and validating measles and rubella elimination. The framework will be finalized after a WHO internal consultation in January 2010.

Recommendations

Technical Session 1: Surveillance of vaccine-preventable diseases in the Region: experiences and challenges from Member States, ECDC and WHO Regional Office for Europe

ETAGE recognizes that WHO and ECDC have different, but complementary, objectives for surveillance of infectious diseases, and that the requirement to respond to the objectives of both WHO and ECDC may place an additional burden on Member States. Delays in reporting present a significant problem for all infectious disease surveillance systems and any additional burden on Member States causes further delays, making it less likely that improvement in the timeliness of reporting will be achieved.

ETAGE recommends the establishment of a Working Group, to include representatives from WHO, ECDC and selected Member States, to rationalize and harmonies requirements and mechanisms for reporting vaccine preventable disease strategic information to WHO and ECDC. Activities of the Working Group should be focussed on establishing a common platform for Member States for reporting surveillance data, with open access to both organizations. In addition, a core variable dataset should be defined from which both organizations can then add other variables. Experience gained through the operation of EUVACNET should be reviewed and utilized.

1. ETAGE recognizes the continuing urgent need to improve pre-service and in-service training for vaccinology and surveillance of VPDs. ETAGE encourages the Regional Office to:
   - develop a platform for sharing best practices in these areas;
• provide advice on national training activities; and
• explore with WHO headquarters the possibility of making vaccinology and surveillance for VPDs a standard global component of medical and allied health education.

ETAGE is concerned with the projected funding gap for 2010–2011. Although a gap often exists at the beginning of a funding biennium, the magnitude of the projected gap, together with anticipated reduced opportunities to meet the currently un-met requirements, have the potential to seriously disrupt Regional immunization activities.

2. ETAGE recommends that:
   • a partner meeting for mobilization of resources for immunization and VPD surveillance in the European Region be held as soon as possible;
   • opportunities for including partners and potential partners in EIW activities should be explored;
   • the process of engaging and involving WHO collaborating centres and other technical institutions in providing technical support and facilitating and conducting activities within the Region should be continued and extended.

Technical session 2: Roles and status of advisory groups at global, regional, and national levels (SAGE, ETAGE and NITAG)

Following requests from Member States for further actions in establishing and strengthening NITAGs, and supporting them through provision of technical information and procedural tools,

3. ETAGE recommends that:
   • the WHO Regional Office continue development of NITAG support and strengthening tools and procedures to establish an effective system of immunization information sharing and exchange, both between Member States and with WHO Regional Office;
   • every opportunity should be taken to make full use of resources and information provided by SAGE;
   • collaborations with other agencies and initiatives, such as SIVAC, should be continued and extended.

Technical Session 3: Vaccine for pandemic (H1N1) 2009 influenza

In response to requests for information regarding use of vaccines against pandemic (H1N1) 2009 influenza, ETAGE:

• endorses the SAGE recommendations that immunization against pandemic (H1N1) 2009 influenza should not alter existing plans for immunization of target groups with vaccine against seasonal influenza, or delay or adjust routine immunization schedules for other antigens;
• endorses the SAGE recommendations on prioritization of groups for receipt of pandemic (H1N1) 2009 influenza vaccine; and
• requests SAGE to address the issues of co-administration of influenza vaccines and age- and group-specific dose requirements at its meeting in October 2009.
4. ETAGE recommends that WHO work with Member States, UNICEF and other agencies to establish methods for identification of unused stocks of pandemic influenza vaccine for provision to Member States that are unable to provide sufficient vaccine to immunize high priority groups.

**Technical Session 4: TDI Strategic Plan**

Recognizing that the Regional TDI Strategic Plan 2010–2014 has been drafted and preparations are in hand to finalize the document,

5. ETAGE recommends the draft Plan be finalized as a working document for distribution. ETAGE expects that this document will be open for periodic review and possible revision through 2014.

**Technical Session 5: Status of 2010 goal for measles and rubella elimination goal**

ETAGE acknowledges the successful efforts made by many Member States to eliminate measles in accordance with the Regional 2010 elimination goal. It notes, however, that a number of Member States, particularly in western Europe, are not only unlikely to meet the 2010 target, but pose a significant threat for exporting measles virus to other Member States. ETAGE recommendations from October 2008 and March 2009 should continue to be followed up by WHO European Regional Office and Member States.
ANNEX 1. PROGRAMME

Tuesday, 29 September

09:15–10:00  Registration  
Registration desk

10:00–10:30  Opening remarks  
WHO Regional Office (WHO Regional Office for Europe)  
Chairperson, Professor P Van Damme

10:30–11:15 Progress since last ETAGE, March 2009  
Dr R Martin

11:15–11:45  Coffee break

11:45–12:30  Technical Session 1: Surveillance of vaccine-preventable diseases in the Region: experiences and challenges from Member States, ECDC and WHO Regional Office for Europe  
Issues for ETAGE:

- Review of reporting requirements of WHO Regional Office for Europe and ECDC on Member States
- Review of strategy and approach to Member States
  - WHO Regional Office for Europe  
    Dr D Mercer
  - ECDC  
    Dr L Pastore-Celentano
  - United Kingdom – Case-based surveillance for measles and rubella  
    Ms H Campbell
  - Turkey – Monitoring surveillance system performance  
    Dr A Coskun

12:30–13:30  Lunch

13:30–15:30  Technical Session 1: (continued)

- Discussion
- Panel discussion (Dr L Pastore-Celentano, Dr S Glissman, Dr H Campbell, Dr A Coskun, Dr L Mosina, Mr A Goel, Dr E Gavrilin, Dr D Mercer)
  Professor D Salisbury

15:30–16:00  Coffee break

16:00–16:30  Targeted Diseases and Immunization Team Updates  
Mr L Weakland

- 2010–2011 activity and financial plan
- Resource mobilization
- European Immunization Week 2009 – report and 2010 planning

16:30–17:30  Private session – ETAGE

18:00–19:00  Reception
Wednesday, 30 September

09:00–10:00  **Technical Session 2: Roles and status of advisory groups at global, regional, and national levels (SAGE, ETAGE and NITAG)**
- Update on SAGE  
  Dr. P. Duclos
- Progress on establishing and strengthening NITAGs  
  Dr. N. Cakmak
- Update from SIVAC Initiative  
  Dr. K. Senouci
- Lessons learned in Kyrgyzstan  
  Dr. N Babadzanov

10:00–11:00  **Technical Session 3: Vaccine for pandemic (H1N1) 2009 influenza:**
**Issues for ETAGE:**
- Which priority groups should be recommended for immunization with pandemic (H1N1) 2009 influenza vaccine?
- What should be the recommendations to Member States about access to pandemic (H1N1) 2009 influenza vaccine?
- What should be the guidance on seasonal influenza vaccination during the pandemic?
  - Regional overview of the pandemic (H1N1) 2009 influenza  
    Dr. J. Mott
  - Regional activities in availability and deployment  
    Dr. N. Cakmak
  - Policy guidance from ETAGE

11:00–11:30  **Coffee break**

11:30–12:00  **Technical Session 4: TDI Strategic Plan**  
Dr. R. Martin
**Issues for ETAGE:**
- Does the strategic plan cover the scope of WHO Regional Office for Europe’s work in immunization?
  - WHO Regional Office for Europe’s Regional Immunization Strategic Plan
  - Discussion

12:00–12:45  **Technical Session 5: Status of 2010 goal for measles and rubella elimination goal**  
Dr. S. Deshevoi
**Issues for ETAGE:**
- Are Member States on track to reach the established targets?
- Are the implemented strategies enough to reach elimination?
  - Status of reaching the 2010 goal for measles and rubella elimination in WHO Regional Office for Europe

12:45–15:00  **Lunch**

12:45–15:00  **Private session and lunch — ETAGE**
- Recommendations
- Membership in 2010

15:00–16:00  **Conclusions and recommendations**  
Chairperson
**Closing remarks**  
WHO Regional Office for Europe
ANNEX 2. PARTICIPANTS

ETAGE Members

Professor Paata Imnadze
Director General
National Center for Disease Control and Public Health (NCDC)
Ministry of Labour
Health and Social Affairs, Tbilisi, Georgia

Dr Mira Kojouharova
Head of Department,
National Center for Infectious and Parasitic Diseases
Ministry of Health
Sofia, Bulgaria

Dr Dilbar Makhmudova
Manager of Child Immunization Project
Scientific Research Institute of Pediatrics
Ministry of Health
Tashkent, Uzbekistan

Dr Patrick Olin
ETAGE Member
Stockholm, Sweden

Professor Christian Perronne (Vice-Chair)
Président
Haut Conseil de la Santé Publique
Hôpital Raymond Poincaré
Garches, France

Professor Tatiana Semenenko
Professor and Head of Laboratory and Department
Gamaleya Institute of Epidemiology and Microbiology
Russian Academy of Medical Services
Moscow, Russian Federation

Professor Pierre Van Damme (Chairperson)
ETAGE
WHO Collaborating Centre
Antwerp (Wilrijk), Belgium

Country Representatives

Turkey
Dr Aslihan Coskun
Ministry of Health
Communicable Diseases and Outbreak Control Department
EPI Unit
Primary Health Care General Directorate
Sihhiye-Ankara, Turkey
United Kingdom of Great Britain and Northern Ireland
Miss Helen J. Campbell
Senior Clinical Scientist (Epidemiology)
Immunisation, Hepatitis and Blood Safety Department
Centre for Infections, Health Protection Agency
London, United Kingdom of Great Britain and Northern Ireland

Other international organizations

CDC
Dr Robb Linkins
Chief, Vaccine Preventable Disease
Eradication and Elimination Branch
Global Immunization Programme
National Immunization Programme, Centres for Disease Control and Prevention (CDC), MS E-05

ECDC
Dr Lucia Pastore-Celentano
Senior Expert in Vaccine Preventable Diseases
Surveillance Unit
European Centre for Disease Prevention and Control (ECDC)
Stockholm, Sweden

Dr Bruno Ciancio
Flu Team
European Centre for Disease Prevention and Control (ECDC)
Stockholm, Sweden

SAGE
Professor David M. Salisbury
Director of Immunization
Department of Health
London, United Kingdom of Great Britain and Northern Ireland

SIVAC
Mr Kamel Senouci
Programme Director, SIVAC Initiative
Supporting National Independent Immunization and Vaccine Advisory Committees
AMP c/o Institut Pasteur
Agence de Médecine Préventive
Paris Cedex 15, France

UNICEF
Dr Oya Zeren Afsar
Immunization Specialist
Health System and Policy
UNICEF CEE/CIS
Geneva, Switzerland
Observers

Other international organizations

_EUVAC.NET_

Dr Steffen Glismann  
Senior Consultant in Public Health Medicine, Department of Epidemiology  
EUVAC.NET Representative  
Statens Serum Institut  
Copenhagen S, Denmark

Dr Mark Muscat  
Department of Epidemiology  
Statens Serum Institut  
Copenhagen S, Denmark

NI TAG representatives

_Alabania_

Dr Arjan Harxhi  
Director General  
Directorate of Hospital Policy and Planning  
Ministry of Health  
Tirana, Albania

Professor Pellumb Pipero  
Assistant Dr.  
Institute of Public Health  
Rruga Aleksander Moisiu, Albania

_Armenia_

Dr Marine Ayvazyan  
Orthopedic and Traumatology Institute  
Yerevan, Armenia

Dr Gayane Sahakyan  
NIP Manager, Senior Specialist  
Communicable Diseases, Sate Hygiene and Anti-Epidemic Inspectorate  
Ministry of Health  
Yerevan, Armenia

Dr Gagik Sayadyan  
Head of Administration  
Ministry of Health of Armenia  
Yerevan, Armenia

_Azerbaijan_

Dr Nasib Guliyev  
Director, Head Pediatrician  
Research Institute of Pediatrician  
Ministry of Health  
Baku, Azerbaijan
Professor Fakhranda Sadikhova  
Head, Department of Epidemiology and Microbiology  
State Institute for Postgraduate Education of Doctors  
Baku, Azerbaijan

_Kyrgyzstan_

Dr Murzaffar Akhmedov  
Head, City Department of Immunoprophylaxis  
Member of the Committee on Immunoprophylaxis  
Osh, Kyrgyzstan

Dr Damira Alieva  
Head, Department of Immunoprophylaxis  
Talas Region  
Member of the Committee on Immunoprophylaxis

_Republic of Moldova_

Dr Victoria Bucov  
Chief, Laboratory of Specific Prophylaxis  
National Research Center for Preventive Medicine  
Chisinau, Republic of Moldova

Dr Anatolie Melnic  
Head, Department of General Epidemiology  
National Research Centre for Preventive Medicine  
Chisinau, Republic of Moldova

_Romania_

Dr Gratiana Chicin  
Head, Epidemiology Department  
Institute of Public Health  
Timisoara, Romania

_Tajikistan_

Dr Dilovarsho Makhmadov  
Director, Center of Immunization Rasht Region  
Rasht Region, Tajikistan

Dr Sohibnazar Turkov  
Deputy Director  
Republican Center of Immunoprophylaxis  
Ministry of Health  
Dushanbe, Tajikistan
Turkey
Dr F. Nur Aksakal
Associate Professor
Department of Public Health
Gazi University, Faculty of Medicine
Halk Sagligi A.D. Besevler
Ankara, Turkey

Uzbekistan
Dr Sanat B. Shoumarov
Chief Physician
Republican Center of State Sanitary Epidemiological Surveillance
Ministry of Health
Tashkent, Uzbekistan

Rapporteur
Dr Raymond Sanders
Scientist
United Kingdom of Great Britain and Northern Ireland

Interpreters
Ms Olga Alexinskaya
Freelance Interpreter/Translator
Moscow, Russian Federation

Dr Oxana Khabib
Interpreter
Moscow, Russian Federation

World Health Organization

Headquarters
Dr Philippe Duclos
Senior Health Adviser
Department of Immunization, Vaccines and Biologicals Immunization Policy

Regional Office for Europe
Dr David Mercer
Unit Head a.i.
Communicable Diseases Unit

Dr Rebecca Martin
Team Leader
Targeted Diseases and Immunization
Communicable Diseases Surveillance

Dr Nilesh Buddha
Consultant
Communicable Diseases Surveillance
Dr Osman Niyazi Cakmak  
Technical Officer  
Immunization Systems Strengthening  
Communicable Diseases Surveillance

Dr Sergei Deshevoi  
Medical Officer  
Measles Elimination, Strengthening Immunization

Dr Eugene Gavrilin  
Coordinator  
EURO Polio Laboratory Network

Mr Ajay Goel  
Technical Officer  
Surveillance, Analysis and Data Management

Dr Dragan Jankovic  
Technical Officer  
Measles/Rubella Special Projects

Dr Liudmila Mosina  
Technical Officer

Mr Joshua A. Mott  
Technical Officer  
Communicable Diseases Surveillance

Dr Anne Marie Wasley  
Consultant  
Communicable Diseases Surveillance

Mr Leo Weakland  
Technical Officer  
Seconded CDC

Ms Sandra Hilaire-Madsen  
Secretarial Assistant  
Targeted Diseases and Immunization  
Communicable Diseases Surveillance

Ms Janet L. Leifelt  
Acting Programme Assistant  
Targeted Diseases and Immunization  
Communicable Diseases Surveillance
The WHO Regional Office for Europe

The World Health Organization (WHO) is a specialized agency of the United Nations created in 1948 with the primary responsibility for international health matters and public health. The WHO Regional Office for Europe is one of six regional offices throughout the world, each with its own programme geared to the particular health conditions of the countries it serves.

Member States

Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and Herzegovina
Bulgaria
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Republic of Moldova
Romania
Russian Federation
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
The former Yugoslav Republic of Macedonia
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan